Clarient to Present at the Rodman & Renshaw Healthcare Conference on November 12.ALISO VIEJO, Calif. -- Clarient, Inc. (Nasdaq:CLRT CLRT Continuous Lateral Rotation Therapy CLRT Command Logistics Review Team CLRT Cranial Laser Release Technique ), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced that its Vice Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Ron Andrews is scheduled to make an investor presentation at the Rodman & Renshaw Healthcare Conference on Wednesday, November 12, 2008 at 9:55 a.m. Eastern time (6:55 a.m. Pacific time). The conference is being held at The Palace Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . A live audio webcast of the Company's presentation at the conference will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the presentation will be available shortly after the presentation time for a period of 90 days. About Clarient Clarient combines innovative technologies with world-class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care, and accelerate the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry flow cytometry (flōˑ sī·t  ˑ·m and molecular testing. Clarient is
that resource, having created a state-of-the-art commercial cancer
laboratory providing advanced oncology testing and drug development
services available both onsite and over the web. Clarient is a Safeguard
Scientifics partner company. www.clarientinc.com.
About Safeguard Scientifics Founded in 1953 and based in Wayne, Penn., Safeguard Scientifics, Inc. (NYSE NYSE See: New York Stock Exchange :SFE See Sydney Futures Exchange. ) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements Capital requirements Financing required for the operation of a business, composed of long-term and working capital plus fixed assets. between $5 million and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. www.safeguard.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion